Journal of leukemia (Los Angeles, Calif.)最新文献

{"title":"Case Report on the Prevention of an Endemic Outbreak of Influenza B on an Allogeneic Transplant Ward","authors":"K. Heidrich, Änne Boldt, F. Stölzel, M. Bornhäuser, J. Schetelig, F. Gunzer","doi":"10.4172/2329-6917.1000205","DOIUrl":"https://doi.org/10.4172/2329-6917.1000205","url":null,"abstract":"Respiratory tract infections pose a threat to hematopoietic stem cell recipients, increasing morbidity and mortality rates. To address this, preventive measures are of great importance. We describe the early detection of influenza B in a patient who received a recent hematopoietic transplantation, and elucidation of the transmission path using a point-of-care multiplex polymerase chain reaction panel, leading to prevention of viral spread. The use of risk-score systems and point-of-care testing should be further evaluated.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Bone Lymphoma of the Patella","authors":"R. E. Vega, S. Lozano-Calderón, Karen M. Chisholm, M. Harris, Megan E Anderson","doi":"10.4172/2329-6917.1000204","DOIUrl":"https://doi.org/10.4172/2329-6917.1000204","url":null,"abstract":"Background: Primary bone lymphoma (PBL) is a rare bone malignancy that accounts for 7% of all bone tumors. It most commonly involves the long bones, with the distal femur and the proximal tibia being the most common locations. The majority of patients present during adulthood with pain in the absence of trauma. Methods: A case report of a 15 year-old male, with a 6-month history of insidious onset right peripatellar pain. After arriving to our clinic he presented with a 30-pound weight loss over the last year, right inguinal adenopathy and tenderness in the patellar area. Imaging showed an osteolytic lesion of the right patella and an imaging-guided biopsy was performed. Awaiting results, he presented with a non-displaced fracture of the patella while he was walking down the stairs. Treatment with a knee brace and COPAD chemotherapy regime was initiated after a diagnosis of bone lymphoma was established. Results: Our patient received 6-months of chemotherapy and knee immobilization for his pathologic fracture. There was good response to the chemotherapy and no complications arised after the fracture. Our patient is now 2-years after diagnosis, without signs of recurring disease and back to his normal daily activities. Conclusion: There are few reports of PBL arising from the patella in the literature. Most of these reports do not distinguish by age, and the few that do, show patients between 38-77 years of age. To our knowledge, this is the first report of a patellar primary bone lymphoma in the pediatric population. Anterior knee pain is extremely common and its differential diagnosis is very wide. Anterior knee pain is more commonly related to tendinitis, patellar malalignment syndrome and chondromalacia. Clinicians should keep in mind the possibility of a malignant process as a possible underlying cause when there is lack of response to conventional treatment.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukemia and Ionizing Radiation Revisited","authors":"J. Cuttler, J. Welsh","doi":"10.4172/2329-6917.1000202","DOIUrl":"https://doi.org/10.4172/2329-6917.1000202","url":null,"abstract":"A world-wide radiation health scare was created in the late 1950s to stop the testing of atomic bombs and block the development of nuclear energy. In spite of the large amount of evidence that contradicts the cancer predictions, this fear continues. It impairs the use of low radiation doses in medical diagnostic imaging and radiation therapy. This brief article revisits the second of two key studies, which revolutionized radiation protection, and identifies a serious error that was missed. This error in analyzing the leukemia incidence among the 195,000 survivors, in the combined exposed populations of Hiroshima and Nagasaki, invalidates use of the LNT model for assessing the risk of cancer from ionizing radiation. The threshold acute dose for radiation-induced leukemia, based on about 96,800 humans, is identified to be about 50 rem, or 0.5 Sv. It is reasonable to expect that the thresholds for other cancer types are higher than this level. No predictions or hints of excess cancer risk (or any other health risk) should be made for an acute exposure below this value until there is scientific evidence to support the LNT hypothesis.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia","authors":"L. Agius","doi":"10.4172/2329-6917.1000203","DOIUrl":"https://doi.org/10.4172/2329-6917.1000203","url":null,"abstract":"Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic stem cells and hemangioblasts in the bone marrow. The ability to suppress almost completely, both in terms of phenotype and cytogenetically, the myeloid cell line expansion by imatinib mesylate is indicative of a phenomenon that depends strictly on the transformed status of the cell of origin in the chronic myeloid leukemia process. It is with relevance to complex participation of the dynamics of the fused BCRABL protein product that contextual conditioning of the cells of origin of the gene translocation further motivates the dimensional expansion of the transformed myeloid cell clones to increasing proliferative rates, thus leading to blast crisis as eventual loss of differentiating potential.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Presentation and Pathology Spectrum of Kidney Damage in Nonhodgkin Lymphoma/Leukemia and Lymphoplasmacytic Lymphomas","authors":"Zakharova Ev, Stolyarevich Es","doi":"10.4172/2329-6917.1000201","DOIUrl":"https://doi.org/10.4172/2329-6917.1000201","url":null,"abstract":"Kidney damage in non-Hodgkin lymphoma/leukemia (NHL/CLL) and lymphoplasmacytic lymphomas (LPCL) are caused by several mechanisms: tumor mass localization; clonal cell expansion; hormones, cytokines and growth factors secretion; metabolic, electrolyte and coagulation disturbances; deposition of paraproteins and treatment complications. Symptoms of kidney damage may dominate and even preclude overt NHL/CLL or LPCL, and only renal pathology findings give the clue to the diagnosis. We aimed to evaluate clinical presentation and pathology of kidney damage in patients with NHL/CLL or LPCL. Using electronic database and purposely designed chart, we searched data for 158 patients with lymphoproliferative disorders (LPD) and pathology proven kidney lesions. Patients with multiple myeloma, Hodgkin’s lymphoma, Castleman disease, “primary” AL amyloidosis and “primary” light chain deposition disease were excluded from further analysis. Study group consisted of 24 patients, 14 (58.3%) male and 10 (41.7%) female, median age 67 (17;76) years. 16 patients (66.6%) were diagnosed with NHL/CLL, 7 patients (29.1%) with Waldenstrom’s Macroglobulinemia (WM) and 1 (4.1%) with Franklin’s disease (FD). 10 (41.7%) of patients presented with nephrotic syndrome (NS), 17 (70.8%)–with impaired kidney function, and 6 (25.2%) with both NS and renal dysfunction. By pathology glomerulonephritis (GN) was found in 11 (45.8%) of patients, in 4 cases GN pattern was associated with monoclonal paraproteins, and in 7 cases GN was considered to be paraneoplastic. Interstitial nephritis was seen in 10 (41.6%) patients, in 8 of them due to specific lymphoid infiltration; and amyloidosis complicated only 3 (12.5%) cases. Patients with NHL/CLL or LPCL, presenting with renal abnormalities, show variety of pathology patterns hardly predictable on clinical basis. Most often in our patient series was specific lymphoid interstitial infiltration and paraneoplastic glomerulonephritis with MN and MPGN patterns. In many cases of NS and/or acute kidney injury (AKI) renal biopsy was crucial for the diagnosis of NHL/CLL and LPCL.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNAs as Biomarkers of the Response to Treatment with ABVD Scheme in Hodgkin Lymphoma","authors":"A. Berg, Le, R. Magalhaes, A. Vidal, Aline Cruz, A. Ribeiro-dos-Santos","doi":"10.4172/2329-6917.1000200","DOIUrl":"https://doi.org/10.4172/2329-6917.1000200","url":null,"abstract":"Hodgkin Lymphoma (HL) is a neoplasia characterized by the restrict number of malignant cells present in the lymph node. Actual criteria in diagnostic standards don’t consider genetic and epigenetic alterations as risk factors in the development of this disease or in the response of the treatment. MicroRNAs (miRNAs) are important regulatory elements of genic expression that can be altered in the presence of cancer. New advances in the field suggest miRNAs as HL biomarkers. We evaluated the expression profiles of five miRNAs (hsa-miR-9, hsa-miR-20a, hsamiR- 21, hsa-miR-26a and hsa-miR-155) in the peripheral blood of three groups of patients: patients diagnosed with HL who had not received any radiologic or chemotherapeutic treatment; patients diagnosed with HL who had been treated with the Adriblastin, Bleomycin, Vinblastine and Dacarbazine (ABVD) chemotherapeutic scheme; and a control group consisting of healthy volunteers without HL. Our results showed that the expression profiles of hsamiR- 9, hsa-miR-21, hsa-miR-26a and hsa-miR-155 were able to significantly distinguish untreated HL patients from patients without the disease and that the hsa-miR-9, hsa-miR-21 and hsa-miR-155 expression profiles were altered by treatment with ABVD. These results suggest that miRNAs are promising blood biomarkers of HL and also a possible biomarkers of the response to ABVD treatment.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2015-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of Inducible Nitric Oxide Synthase to the Transformation of HTLV-1 Infected CD4+ T-Cells","authors":"H. Baydoun, L. Ratner","doi":"10.4172/2329-6917.1000199","DOIUrl":"https://doi.org/10.4172/2329-6917.1000199","url":null,"abstract":"The Human T-cell Leukemia Virus type 1 (HTLV-1), is the first retrovirus associated with a human cancer. HTLV-1 is the causative agent of an aggressive and fatal malignancy of CD4+ T lymphocytes known as Adult T-cell Leukemia lymphoma (ATLL). Since the discovery of the virus in 1980, intensive investigations have been undertaken to determine how HTLV-1 drives the transformation process in infected cells. This is because the oncogenic features of HTLV-1 make it an excellent tool to dissect the molecular pathways involved in cancer development. More important, HTLV-1 induced leukemia is a typical inflammation-mediated malignancy with constitutive activation of the NF-kB pathway, which is also a critical determinant in many other cancers. How NF-kB contributes to the leukemogenic process is not completely defined. We recently demonstrated that the NF-kB pathway induces the expression of inducible nitric oxide synthase (iNOS) in HTLV-1 induced leukemia. iNOS enzymatically generates nitric oxide, which is an oxidative and nitrosative agent of DNA and protein. Nitric oxide was found to be associated with a large number of DNA Double Strand Breaks (DSBs) in HTLV-1 transformed cells. Here, we will review the major effects of nitric oxide on HTLV-1 induced leukemia.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2015-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemophagocytic Lymphohistiocytosis Due to Acute Myeloid Leukemia Relapse: A Very Unusual Association","authors":"Maya Belhadj, B. Burroni, F. Suarez, F. Pène, N. Chapuis, S. Pilorge, L. Willems, P. Franchi, B. Deau, D. Bouscary, J. Tamburini, M. L. Goff","doi":"10.4172/2329-6917.1000198","DOIUrl":"https://doi.org/10.4172/2329-6917.1000198","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) diagnosed in the course of acute myeloid leukemia (AML) is generally triggered by treatment-induced infections. AML-induced HLH is a very rare situation for which no diagnostic or therapeutic guidelines are available. We report the occurrence of HLH in an AML5 post-transplant relapse. In our case, the absence of detectable pathogen and the parallel evolution between HLH and leukemia burden suggested a direct link between AML and HLH. We suggest that the diagnostic of AML-related HLH should be promptly considered in front of unexplained fever, cytopenia, liver dysfunction or neurological symptoms as therapeutic intervention is urgent in this life-threatening situation.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy in Cutaneous B-Cell Lymphomas Treatment: Report of Three Cases","authors":"M. Molgó, J. Rodríguez, Camila Arriagada, E. Vinés, F. Fich, Katherine Droppelmann, S. González","doi":"10.4172/2329-6917.1000197","DOIUrl":"https://doi.org/10.4172/2329-6917.1000197","url":null,"abstract":"Introduction: Primary cutaneous lymphomas (PCL) are a heterogeneous group of extra nodal non-Hodgkin lymphomas defined as malignant tumor derived from B, T or natural killer cells. Primary cutaneous follicle centre lymphoma (PCFCL), represents the most common type of primary cutaneous B- Cell Lymphomas. \u0000Case Report: We present the case of three female patients with facial PCFCL, all of them with excellent respond to radiotherapy. \u0000Discussion: Multiple treatments for PCFCL have been described, including systemic or intralesional Rituximab, surgery or radiotherapy. We present these 3 cases of PCFLC treated with radiotherapy in our service, because of the excellent response, confirming radiotherapy as a therapeutic alternative.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Baseline Health-Related Quality of Life in Real-Life Patientswith Monoclonal Gammopathies","authors":"R. Ríos-Tamayo, J. Sainz, M. Jurado","doi":"10.4172/2329-6917.1000196","DOIUrl":"https://doi.org/10.4172/2329-6917.1000196","url":null,"abstract":"Health-related quality of life (HRQoL) is increasingly used as a secondary end-point in clinical trials, in particular, in multiple myeloma (MM)-related studies. However, several issues preclude a generalized use. First, the evidence available is still scarce; furthermore, some weaknesses and inconsistencies in analysis and presentation are observed [1]. Second, standardization for data collection, analysis and reporting is lacking. Third, an internationally validated questionnaire should be used.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}